Letermovir
Prevymis (letermovir) is a small molecule pharmaceutical. Letermovir was first approved as Prevymis on 2017-11-08. It has been approved in Europe to treat cytomegalovirus infections. Prevymis's patents are valid until 2033-02-28 (FDA).
Trade Name | Prevymis |
---|---|
Common Name | Letermovir |
Indication | cytomegalovirus infections |
Drug Class | Antivirals |